Prestige Consumer Healthcare raises fiscal 2027 outlook after two acquisitions close

Prestige Consumer Healthcare reported first quarter fiscal 2027 results on August 6, 2026 for the period ended June 30, 2026. The company closed the Breathe Right acquisition late in the quarter, which added an incremental $6 million in revenue, and said the brand is positioned well for long-term growth.¹ The LaCorium acquisition closed in July, after the Breathe Right deal closed in June.¹

Following the two deals, the company said it was raising its fiscal 2027 outlook for both revenue and EPS entirely to account for the two acquisitions, which it said add nearly 20% to its revenue base, with expectations that the deals become increasingly accretive to profitability and cash flow as synergies and brand growth objectives are realized.¹ The updated outlook calls for revenue of $1,290 to $1,315 million, versus an initial outlook of $1,100 to $1,121 million, and adjusted diluted EPS of $4.55 to $4.65, up from an initial range of $4.42 to $4.51. Adjusted free cash flow guidance was raised to $270 million or more from $250 million or more.¹

On the balance sheet side, the company's net debt position as of June 30, 2026 was approximately $2 billion, and subsequent to the quarter, on July 15, 2026, the company issued $400 million of new 6.25% senior notes due 2034, replacing the same principal amount of notes previously due in fiscal 2028, which extended the company's closest debt maturity to 2031.¹

Executives also flagged an ongoing supply issue with one product line. Management said its portfolio diversity and business attributes leave it positioned to manage the continued volatile supply for Clear Eyes.¹